The overall vision of Immunitrack is to enable better patient care through improved immunotherapy and the mission is to advance the most reliable platform in predicting and validating T cell epitopes. How can Immunitrack Help R&D? The Major Histocompatibility Complex (MHC) is critical to the immune response. Immunitrack has world-leading expertise in the manufacture and application of MHC I and II molecules to accurately study MHC epitope binding through our proprietary NeoScreen platform. Major Areas of Application • Immuno-oncology: selection and study of neo-epitopes for personalized cancer vaccine development • Vaccine development: selection of immunogenic epitopes from viral and bacterial targets • Reducing immunogenicity of biologics: reduce the risk of anti-drug antibody development by identifying and removing CD4 T cell epitopes in candidate biologics. • Advance novel TCR-like antibodies, from target discovery to generating and characterising TCR-LA Reagents We produce customized MHC tetramers to detect and quantify subsets of patient immune (T) cells with specificity towards a given antigen within blood samples. All of our MHC I reagents are produced on our optimized manufacturing platform, and we guarantee 100% peptide loading of each complex. Binding Assays Our unique NeoScreen® platform combines more than a decade of world-leading expertise in MHC/epitope binding assays with a high level of automation. The result is a highly scalable and accurate platform that can screen thousands of (neo-)epitopes. Depending on the desired immune response our clients can then select and progress the best candidates through therapeutic development. Our repository is continuously growing, and currently holds more than 70 different MHC I and 20 MHC II alleles.